Our mission is to save lives through the prediction and earlier detection of cancer.

Our Test

EsopredictTM is a molecular test that provides personalized guidance for Barrett’s esophagus surveillance and treatment decisions.

Learn More:

Ordering Information

EsopredictTM is only available through a licensed healthcare provider. Click the button below for more information.


Explore information about esophageal cancer and the precancerous condition called Barrett’s esophagus.

Esophageal cancer is a global concern.

In 2023, an estimated 21,560 people will be diagnosed with esophageal cancer in the United States and about 16,120 people will die from the disease before the year ends.1 Globally, it is estimated that between 2020-2040, there will be a 50% increase in new cases of esophageal cancer or over 1 million people diagnosed.2

Conquering esophageal cancer is only the beginning.

At Previse, we are developing precision medicine solutions aimed at prevention and earlier detection of cancer, starting with esophageal cancer. Our solutions are built upon a foundation of proprietary epigenetic biomarkers and strong data science to support diverse clinical study populations around the world.

man and woman sitting on sofa and laughing

Information for Patients

EsopredictTM offers timely insights to you and your healthcare provider about your future risk of progressing from having Barrett’s esophagus to esophageal cancer. Explore this section for more information.

Physician and patient looking at a tablet and smiling

Information for Healthcare Providers

Explore how the EsopredictTM test and the EsoscoreTM report can be used to help your patients understand their future risk of progression from Barrett’s esophagus to esophageal cancer and the steps they can take to treat their condition.